PPI users at increased risk of atherosclerotic cardiovascular diseases, finds study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-09 04:30 GMT   |   Update On 2022-09-09 05:51 GMT

China: Research published in the journal Atherosclerosis has linked protein pump inhibitors (PPIs) with an increased risk of atherosclerotic cardiovascular diseases (ASCVDs). The trouble was mainly seen in patients without indications for medications.

Based on the study findings, the research team led by Yue Ma, School of Public Health, Tianjin Medical University, Tianjin, China, has cautioned clinicians against the prophylactic use of PPIs.

There have been increased concerns regarding adverse events associated with acid suppressant use. Proton pump inhibitors are medications that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. in recent years. However, the impact of PPIs and histamine‐2 receptor antagonists (H2RAs) on ASCVDs risk is unknown.

Considering the above, the researchers from China aimed to estimate the risk of ASCVDs associated with using H2RAs and PPIs in a prospective cohort study.

Advertisement

The study included patients in the UK Biobank (2006–2010) without cardiovascular diseases or anti-hypertensive treatment at baseline. ASCVDs and each subtype (myocardial infarction, coronary artery disease, ischemic stroke, and peripheral artery disease) were the study outcomes. Cox proportional-hazards models were used to estimate the association.

During a median of 12.5 years of follow-up, the authors documented 13,503 (4.3%) incident ASCVDs among 316,730 individuals (aged 50–88 years).

The researchers reported the following findings:

  • Regular PPIs use was associated with a higher risk of ASCVDs (HR: 1.16) and every subtype of ASCVDs.
  • Among each type of PPIs, lansoprazole (HR: 1.11), omeprazole (HR: 1.19), and pantoprazole (HR: 1.40) were associated with a higher risk of ASCVDs.
  • Stratification analysis showed that PPIs use was associated with a higher risk of ASCVDs among individuals without indications of medications for PPIs.
  • In addition, H2RAs use was not related to the risk of ASCVDs (HR: 0.97).

The researchers conclude, "higher ASCVD risk was observed among PPI users without indications for medication, particularly amongst participants without indications for medication."

Reference:

The article "Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults" was published in Atherosclerosis.

https://doi.org/10.1016/j.atherosclerosis.2022.09.001



Tags:    
Article Source : Atherosclerosis

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News